Answers are grounded in this paper and cite their sources.
The instability of a breast cancer subtyping scheme like PAM50 could have important consequences in clinical management of patients. AIMS is a fully stable and robust subtyping scheme that recapitulates PAM50.
No takes yet. Share an insight, caveat, or question.
Paquet et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: